Biotech Specialty Pharma


300 Technology Square, 3rd Floor
Cambridge, MA 02139 USA
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Technologies that induce or remove immunological tolerance.

Management Douglas J. Ringler, V.M.D., Co-Founder, President & Chief Executive Officer; Herman Waldmann , Ph.D., FRCPath, MRCP, FRS, FMedSci, Co-Founder, Chairman, Scientific Advisory Board; Louis Vaickus, M.D., Chief Medical Officer; Thomas A. Shea, M.B.A., Chief Financial Officer

Click here for Financial Data
Keywords: cancer, monoclonal antibodies, Diabetes, blood sugar, diabetic, metabolic, insulin, immune system, psoriatic arthritis, autoimmune disease


Updated: Jan. 15, 2009


TolerRx specializes in the discovery and development of therapies that induce or remove immunological tolerance. The Company's therapies are designed to reprogram the immune system and provide a stabl......view more

Products / Services

TolerRX's TRX4 is a humanized monoclonal antibody that binds to a receptor found on all T-cells called CD3, which is involved in normal T-cell signaling. TRX4 is designed to block the function of T-ef......view more

Technology / Differentiation

T cells are at the heart of most immune responses. TolerRX has focused its research on T-regulatory cells which can actively suppress the generation and function of T-effector cells. T-regulatory cell...view more